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Positron emission tomography to image cerebral
neuroinflammation in ischaemic stroke: a pilot study
Eszter Visio ,1 Rainer Hinzo ,1 Martin Puntero ,2 Arshad Majid,3
Alexander Gerhardo 1,4,5 and Karl Herholzo 1*
1Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre,
University of Manchester, Manchester, UK
2Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford, UK
3Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK
4Department of Geriatric Medicine, University Hospital Essen, Essen, Germany
5Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
*Corresponding author karl.herholz@manchester.ac.uk
Background: Activated microglia play a complex role in neuroinflammation associated with acute ischaemic
stroke. As a potential target for anti-inflammatory therapy, it is crucial to understand the association between
intensity, extent and the clinical outcome of a stroke. The 18-kDa translocator protein is a marker of cerebral
microglial activation and of macrophage infiltration after damage to the brain. It can be imaged by positron
emission tomography. Therefore, the recently developed radiopharmaceutical [18F]-GE180 was used in
patients after a mild to moderate stroke and compared with [11C]-(R)-PK11195, which has already been
established in research but cannot be used in routine clinical settings because of its very short half-life.
Objectives: Objectives for phase 1 were to evaluate the tolerability of positron emission tomography
scanning, to assess the technical feasibility of imaging the 18-kDa translocator protein using [18F]-GE180 as
radiopharmaceutical, to compare [18F]-GE180 with [11C]-(R)-PK11195 as reference. Objectives for phase 2
were examining the relation of positron emission tomography imaging with clinical outcome, magnetic
resonance imaging and systemic inflammation. However, the study was ended after phase 1 because
of the results obtained in that phase and did not enter phase 2.
Methods: Ten participants (aged 24–89 years, median 68 years) (eight male and two female) with a
history of recent ischaemic stroke of mild to moderate severity (modified Rankin scale score of 2–3) in
the middle cerebral artery territory were scanned 18 to 63 days (median 34.5 days) after the stroke by
magnetic resonance imaging (Philips 1.5 T; Philips, Amsterdam, the Netherlands), [18F]-GE180 (200 MBq,
30-minute dynamic scan) and [11C]-(R)-PK11195 (740 MBq, 60-minute dynamic scan) positron emission
tomography (Siemens HRRT; Siemens, Munich, Germany). The two positron emission tomography scans
were performed on 2 separate days (mean 3.4 days apart). Five patients were randomised to receive the
[18F]-GE180 scan at the first session and five patients were randomised to receive it at the second session.
Participants were genotyped for the rs6971 18-kDa translocator protein polymorphism, which is known to
affect binding of [18F]-GE180 but not of [11C]-(R)-PK11195. All positron emission tomography and magnetic
resonance data sets were co-registered with T1-weighted magnetic resonance image scans. Binding of
[18F]-GE180 was compared with [11C]-(R)-PK11195 for the infarct and contralateral reference regions.
Spearman’s rank-order correlation was used to compare tracers, t-tests to compare patient subgroups.
Results: Tolerability of scans was rated as 4.36 (range 4–5) out of a maximum of 5 by participants, and there
were no serious adverse events. There was a close correlation between [18F]-GE180 and [11C]-(R)-PK11195
(r = 0.79 to 0.84). The 18-kDa translocator protein polymorphism had a significant impact on the uptake of
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[18F]-GE180, which was very low in normal cortex. Ischaemic lesions with contrast enhancement on magnetic
resonance as an indicator of blood–brain barrier damage showed a significantly higher uptake of [18F]-GE180
than the lesions without enhancement, even in low-affinity binders.
Conclusions: [18F]-GE180 was safe and well tolerated. However, strong dependency of uptake on
blood–brain barrier damage and a genetic 18-kDa translocator protein polymorphism, as well as a high
contribution of vascular signal to the uptake and evidence of non-specific binding in ischaemic lesions with
blood–brain barrier damage, limits the clinical applicability of [18F]-GE180 as a diagnostic marker of
neuroinflammation.
Limitations: As the study was ended after phase 1, this was only a small pilot trial. Further studies are
warranted to fully understand the influence of blood–brain barrier damage on positron emission tomography
microglia imaging.
Trial registration: Registered as a clinical trial with EudraCT 2014-000591-26.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research
Council and National Institute for Health Research (NIHR) partnership, and will be published in full in Efficacy
and Mechanism Evaluation; Vol. 7, No. 1. See the NIHR Journals Library website for further information.
It was also supported by GE Healthcare (Chicago, IL, USA) by free production and delivery of [18F]-GE180
and by supply of regulatory documents (Investigational Medical Product Dossier, Investigator’s Brochure).
There was partial support by the European Commission (INMiND, grant #278850) and the NIHR Sheffield
Biomedical Research Centre.
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Following a stroke, brain inflammation may occur as a reaction. It is unknown whether or not this reactioncontributes to healing and recovery after stroke or whether or not it can cause further damage that could
potentially be treated by drugs directed against inflammation. Standard investigation methods cannot
determine whether or not there is brain inflammation after stroke. Therefore, a specific brain scanning
method was employed (i.e. positron emission tomography) to investigate this. Positron emission tomography
scanning requires the intravenous injection of radioactive indicators.
In the first phase of our study, we compared two such indicators. One of them had already been used
in stroke patients previously, but is not available for routine use in NHS clinics. The other was a recently
developed new indicator, called flutriciclamide otherwise known as [18F]-GE180, which could potentially be
supplied to hospitals. We found that both indicators were well tolerated and provided similar information.
However, the new indicator showed some problems that would preclude its diagnostic use in patients
with stroke. It did not enter the brain sufficiently well enough and the results depended on confounding
factors. Confounders were a common genetic variant in people that is not related to stroke, and changes
in blood vessels that can occur after stroke but are not directly related to inflammation. We therefore
closed the study after this pilot phase and could not check whether or not there is a link between brain
inflammation and clinical recovery.
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Activated microglia play a complex role in neuroinflammation associated with acute ischaemic stroke.
As a potential target for anti-inflammatory therapy, it is crucial to understand the correlation between its
intensity, extent and the clinical outcome of the stroke.
The 18-kDa translocator protein is a marker of cerebral microglial activation and of macrophage infiltration
after damage to the brain, and it can be imaged by positron emission tomography. The ‘gold standard’
for imaging 18-kDa translocator protein is the radiopharmaceutical [11C]-(R)-PK11195. However, the very
short half-life of 11C is unsuitable for widespread clinical use, whereas 18F-labelled compounds could be
potentially applied as diagnostic tools in routine clinical settings.
We therefore studied microglia activation in the human brain using the recently developed
radiopharmaceutical [18F]-GE180 with positron emission tomography in patients after mild to moderate
stroke.
Objectives
Objectives for phase 1 were to:
1. evaluate the tolerability of positron emission tomography scanning using a questionnaire given to
the participants
2. assess the technical feasibility of imaging the 18-kDa translocator protein (TSPO) using [18F]-GE180 as
a radiopharmaceutical
3. correlate imaging measures obtained with [18F]-GE180 in focal abnormalities with [11C]-(R)-PK11195 as
a reference.
Objectives for phase 2 were examining the relation of positron emission tomography imaging with a
clinical outcome, magnetic resonance imaging and systemic inflammation. However, the study was ended
after phase 1 because of the results obtained in that phase and did not enter phase 2.
Methods
Ten participants (aged 24–89 years, median 68 years) (eight male and two female) who suffered ischaemic
stroke of mild to moderate severity (modified Rankin scale score of 2–3) in the middle cerebral artery territory
were enrolled to the study 4–28 days (median 12 days) after the clinical event. Patients were recruited,
consented and assessed clinically at multiple sites in the Greater Manchester Stroke Operational Delivery
Network. Five more participants were consented but subsequently withdrawn before receiving the scans.
Inclusion criteria
l Aged ≥ 18 years.
l ≤ 4-week history of ischaemic stroke in middle cerebral artery territory at the time of screening for
study inclusion, confirmed clinically or by computed tomography or magnetic resonance imaging scans.
l Mild to moderate severity (modified Rankin scale score of 1–3).
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Participants had to have been able to give informed consent either written or verbally, or in the presence
of at least one witness if they were unable to sign or mark the consent form because of mobility issues.
The witness(es) signed the consent form as evidence that the information was accurately explained to,
and understood by, the participant and that consent was freely given.
Exclusion criteria
l Neurological diagnosis of neurodegenerative disease.
l Inability to understand study information and/or express willingness to consent to the study because of
communication difficulties.
l History of brain surgery, brain tumour, neuroinflammatory or neurodegenerative disease.
l Severe uncontrolled systemic illness.
l Patients in whom carotid endarterectomy/carotid stenting is due to be carried out within 3 months of
recruitment to the study.
l Treatment with other drugs known to influence microglial activation (e.g. minocycline, corticosteroids or
benzodiazepines) (2 weeks prior to date of the scan).
l Pregnancy/breastfeeding women.
l Contraindications to MRI scanning.
l Patients receiving treatment with disulfiram (Antabuse®, Actavis).
Clinical data were recorded at the recruitment sites by the clinical fellow and transmitted to the Christie
(now University of Manchester) clinical trials unit. At the clinical trials unit, the data were controlled for
quality, curated and presented to the chief investigator for scientific evaluation.
Patients were scanned at the Wolfson Molecular Imaging Centre, Manchester, 18 to 63 days (median
34.5 days) after the stroke by magnetic resonance imaging (Philips 1.5 T; Philips, Amsterdam, the Netherlands),
[18F]-GE180 (200MBq, 30-minute dynamic scan) and [11C]-(R)-PK11195 (740MBq, 60-minute dynamic scan)
positron emission tomography (Siemens HRRT; Siemens, Munich, Germany). At the Wolfson Molecular
Imaging Centre, venous blood samples were also taken to look for systemic inflammation markers (C-reactive
protein, interleukin 6).
The two positron emission tomography scans were performed on 2 separate days (median 3.4 days apart).
Five patients were randomised to receive the [18F]-GE180 scan at the first session and five patients were
randomised to receive it at the second session. Participants were genotyped for the rs6971 18-kDa translocator
protein polymorphism, which is known to affect binding of [18F]-GE180 but not of [11C]-(R)-PK11195.
All positron emission tomography and magnetic resonance data sets were co-registered with T1-weighted
magnetic resonance image scans. Binding of [18F]-GE180 was compared with [11C]-(R)-PK11195 for the
infarct and contralateral reference regions. Spearman’s rank-order correlation coefficient was used to compare
tracers and t-tests were used to compare patient subgroups.
Image data acquisition and analysis was performed at the Wolfson Molecular Imaging Centre by the study
chief investigator with co-investigators and staff under the Wolfson Molecular Imaging Centre quality
assurance system, which has undergone regular successful reviews by the Medicines and Healthcare
products Regulatory Agency.
Results
The mean score from the 10 participants’ tolerability questionnaire was 4.36 (range 4 to 5), which is well
above the threshold (neutral = 3) that we set to accept.
SCIENTIFIC SUMMARY
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We did not observe any serious adverse events. Non-serious adverse events occurred but had no obvious
link to the tracer.
A close correlation between [18F]-GE180 and [11C]-(R)-PK11195 (correlation coefficient range 0.79–0.84)
was observed. Genotyping showed that eight patients were high- or mixed-affinity binders for [18F]-GE180.
[18F]-GE180 does not provide a specific 18-kDa translocator protein signal in low-affinity binders (two
patients). Ischaemic lesions with contrast enhancement on magnetic resonance showed significantly higher
uptake of [18F]-GE180 than lesions without enhancement and, even in low-affinity binders, [18F]-GE180
binding in normal cortex was very low with significant dependency on genetic polymorphism. Three patients
had elevated levels of interleukin 6 and high-sensitivity C-reactive protein and they also showed significantly
higher lesion-to-reference ratios with [11C]-(R)-PK11195 (p = 0.005, t-test) and [18F]-GE180 relative to the rest
of the participants with normal inflammatory marker levels.
The pilot phase of this study had not been powered to demonstrate associations with clinical outcome.
As expected, none of the imaging data or plasma markers showed significant correlations with clinical
outcome in this small pilot sample.
Conclusions
[18F]-GE180 positron emission tomography scanning was safe and well tolerated. However, a strong
dependency of uptake on blood–brain barrier damage and a genetic 18-kDa translocator protein
polymorphism, as well as a high contribution of vascular signal and non-specific binding to the uptake
in ischaemic lesions with blood–brain barrier damage, limits the clinical applicability of [18F]-GE180 in
acute stroke.
Because of these limitations, the present study could not be progressed beyond the pilot phase. Further
research is needed to investigate the relation between microglial activation in ischaemic stroke and outcome,
and to establish an imaging technique of microglial activation that could be applied in clinical stroke trials
and services.
Trial registration
Registered as a clinical trial with EudraCT 2014-000591-26.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council and National Institute for Health Research (NIHR) partnership. It was also supported by GE Healthcare
(Chicago, IL, USA) by free production and delivery of [18F]-GE180 and by supply of regulatory documents
(Investigational Medical Product Dossier, Investigator’s Brochure). There was partial support by the European
Commission (INMiND, grant #278850) and the NIHR Sheffield Biomedical Research Centre.
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S troke is the third most common cause of disability in the developed world and the second leading cause ofdeath worldwide.1 According to the Stroke Association (London, UK), stroke is responsible for > 100,000
hospital admissions per year in the UK and the annual cost to UK society is around £26B.
Acute ischaemic stroke is typically caused by a cerebral artery occlusion because of local thrombosis or
thromboembolism from a remote source. Duration and severity of the diminished cerebral blood flow are
the major factors that determine the degree of the ischaemic injury. Hence, prompt reperfusion therapy
using either systemic thrombolysis or endovascular mechanical thrombectomy is the mainstay of acute
treatment. However, given the narrow therapeutic window, only a minority of patients are eligible and can
benefit from these procedures.
Experimental and clinical studies have demonstrated the complex role of the immune system in the molecular,
cellular and tissue changes that occur after acute ischaemic stroke from the early to the late phases.2 Thus,
targeting neuroinflammation became a potential novel therapeutic strategy. The broader therapeutic window
could enable a wide range of patients (relative to the reperfusion procedures) to receive anti-inflammatory
agents, but it might also increase the rate of systemic infectious complications.3 Another potential pitfall can
result from the complex character of the inflammatory process. Often referred to as ‘the double-edged sword’,
neuroinflammation can contribute to tissue damage but also promote repair in the subacute and chronic
phase.2,4 Therefore, understanding the correlation between the grade and extent of neuroinflammation and
the functional outcome could help to establish the optimum timing and monitor the anti-inflammatory
treatment.
Microglia are the major resident immune cells of the brain. Activated microglia respond to pathogens
and neuronal damage and then play a crucial role in mediating the inflammatory response in the brain.5
Hence, microglial activation is a hallmark of neuroinflammation. The 18-kDa translocator protein (TSPO) is
expressed within activated microglia, infiltrating macrophages, astrocytes and endothelial cells. Although
macrophage infiltration is high in acute stroke, in the subacute phase microglia are the predominant
TSPO-expressing cell type.6 Thus, TSPO imaging by positron emission tomography (PET) has been considered
an in vivo marker of activated microglia levels in the brain.7
The first-generation TSPO ligand radiotracer 11C-labelled PK11195 has been successfully used to image
activated microglia in several neurological disorders, including ischaemic stroke.8–11 However, its short
physical half-life (20 minutes) makes it impractical for routine clinical application. In contrast, 18F-labelled
radiopharmaceuticals have a longer half-life, enabling transport from production to clinical sites to occur.
Therefore, they can potentially be applied as diagnostic tools in routine clinical settings.
We therefore studied microglial activation in the human brain using [18F]-GE180 PET in patients after mild to
moderate stroke. In the pilot study we evaluated safety, tolerability and technical feasibility by intraindividual
comparison with [11C]-(R)-PK11195 and assessing the effect of the genotype on the binding. [18F]-GE180 binds
with high specificity to TSPO12 but, similar to second-generation TSPO ligand tracers, affinity is influenced by a
genetic polymorphism (Ala147Thr) on the TSPO gene (rs6971).13 High-affinity binders (HABs) and low-affinity
binders (LABs) express a single binding site for TSPO with either high or low affinity, respectively, whereas
mixed-affinity binders (MABs) express approximately equal numbers of the HAB and LAB-binding sites.14 The
highest specific binding of [18F]-GE180 is expected in HABs, lower but still detectable binding is expected in
MABs, and negligible binding is expected in LABs. If successful, this pilot study was intended to be followed
by a second phase to assess the correlation between the imaging finding and clinical outcome in a larger
patient sample.
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E ligible patients were identified and consented by Greater Manchester hospitals stroke services. Clinicalassessment was performed at the screening visit 4–28 days (median 12 days) after stroke onset and the
3-month follow-up visit was 85–130 days (median 94.5 days) after stroke onset.
A total of 10 participants (eight male and two female) (aged 24–89 years, median 68 years) with ischaemic
stroke of mild to moderate (modified Rankin scale score of 2–3, National Institutes of Health Stroke Scale
score of 0–3) severity in middle cerebral artery territory were scanned. Two of these patients had received
intravenous thrombolysis treatment with recombinant tissue plasminogen activator. Table 1 shows the
demographic and clinical details.
The 3-month follow-up data were collected from eight participants; two participants were lost to follow-up
(Table 2).
TABLE 1 Demographics and clinical symptoms
Participant Age (year) Gender Thrombolysis Clinical symptoms
P002 68 Male No L hemianopsia, L inattention, L hemiparesis
P005 86 Male No R facial droop, dysarthria, mild expressive dysphasia
P006 89 Male No Confusion/speech difficulty/impaired recall of events
P008 53 Male No R hemiparesis and sensory loss
P009 24 Male No L upper limb sensory loss, mild expressive dysphasia
P010 81 Male No L hemiataxia, L sensory loss, dysarthria,
P011 68 Female No Expressive dysphasia
P012 65 Male Yes Expressive dysphasia, R hemianopsia
P014 70 Male Yes R hemiparesis
P015 63 Female No R hemiparesis, R inattention, R paraesthesia, dysarthria
L, left; R, right.
Five further participants (i.e. P001, P003, P004, P007 and P013) were consented but subsequently withdrawn before
receiving scans.
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TABLE 2 Clinical scores
Participant
Modified Rankin scale score National Institutes of Health Stroke Scale
Pre stroke Screening 3-month follow-up Admission Screening 3-month follow-up
P002 0 2 1 17 3 1
P005 1 2 1 2 0 0
P006 2 2 3 7 0 0
P008 0 3 n/a 3 1 n/a
P009 0 2 2 4 2 1
P010 1 2 2 Missing 0 1
P011 0 2 1 2 1 0
P012 0 2 1 3 3 0
P014 0 2 0 9 1 0
P015 0 2 n/a 6 1 n/a
n/a, not applicable.
PATIENTS




All of the participants were scanned at the Wolfson Molecular Imaging Centre 18 to 63 days (median
34.5 days) after their stroke. The participants underwent magnetic resonance imaging (MRI) (Philips 1.5 T;
Philips, Amsterdam, the Netherlands) and PET (Siemens HRRT; Siemens, Munich, Germany) scanning using
[18F]-GE180 and [11C]-(R)-PK11195 tracers.
The two PET scans were performed on two separate sessions as close to each other as possible (mean
3.4 days) but at least 1 day apart. Five participants were randomised to receive the [11C]-(R)-PK11195 at
the first session (arm A) and five participants were randomised to receive the [18F]-GE180 scan at the first
session (arm B).
The MRI scan was performed either during session 1 (nine participants) or during session 2 (one participant).
Eight participants completed T1 inversion recovery, T2 fluid-attenuated inversion recovery (FLAIR) and
post-contrast-enhanced T1 sequence. Two participants completed the non-contrast sequences only because
of safety reasons (allergy or impaired renal function).
Positron emission tomography image processing and analysis
The volume of interest (VOI) of ischaemic lesions (target) were defined manually using ANALYZE software
(Overland Park, KS, USA) on co-registered T2-weighted FLAIR magnetic resonance (MR) scans, separately
for contrast-enhancing and non-contrast-enhancing areas on co-registered T1-weighted MR scans.
Contralateral mirror VOIs were then drawn manually as a reference.
A set of standard anatomical VOIs was placed on the individual PET images by warping the 83-region
probabilistic brain atlas15 from template space. Using the segmented T1-weighted MR scans, a set of
standard grey matter anatomical VOIs was obtained, including left and right cerebellum.
The [11C]-(R)-PK11195 PET data were acquired for 60 minutes following the administration of a 740-MBq activity
intravenous bolus. Parametric maps of binding potentials were generated with the simplified reference tissue
model using a bilateral grey matter cerebellar reference tissue input function.16,17 For better comparability
with the [18F]-GE180 data, [11C]-(R)-PK11195 binding potentials were converted into [11C]-(R)-PK11195
distribution volume ratios by adding the value of 1.18
The [18F]-GE180 PET data were acquired for 30 minutes following the administration of a 200-MBq activity
intravenous bolus. This short measurement time is not sufficient to calculate binding potentials. Instead, two
summed images were calculated: (1) a late summed image 15–30 minutes post injection; and (2) an early
summed image 0–5 minutes post injection, representing predominantly vascular activity. As shown in a
previous study,13 the signal from intravascular activity of [18F]-GE180 remains very high during the scanning
time. In addition to tissue activity without correction obtained from the late summed images, we estimated
intravascular activity from the early summed images and then calculated tissue activity corrected for
intravascular activity by subtracting the estimated intravascular activity from the late summed images.
Target-to-reference ratios (TRRs) of [18F]-GE180 were then calculated from the readouts of the late summed
images without or with correction for vascular activity. TRRs of [11C]-(R)-PK11195 were obtained by dividing
distribution volume ratios of the target (infarct) region through the corresponding reference (contralateral
mirror) region.
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Blood tests
Each participant was genotyped for the rs6971 polymorphism of the TSPO gene [single nucleotide
polymorphism analysis at rs6971 locus using isolated deoxyribonucleic acid by LCG genomics (Hoddesdon,
UK)] and categorised as a HAB, a MAB or a LAB.14 Spearman’s rank-order correlation and unpaired t-tests
were used to test for association of imaging parameters with genotype.
Blood samples were taken from each patient for systemic inflammatory marker [high-sensitivity C-reactive
protein (CRP) and interleukin 6] analysis at the [18F]-GE180 PET session (18–55 days after stroke onset).
Safety and tolerability
Each participant completed a questionnaire after receiving [18F]-GE180 PET to evaluate the tolerability
of scanning. The questionnaire contained five questions asking the participant to grade the discomfort
associated with the [18F]-GE180 PET procedure on a five-point scale (1 – the most discomfort, 5 – the least
discomfort).
All adverse events related to trial-specific procedures were collected.
METHODS
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Chapter 4 Results
Characteristics of patients and their ischaemic lesions
All study participants showed ischaemic lesions associated with the recent ischaemic stroke. A total of
14 lesions in nine patients were detected on the MR scans. In one patient’s case (P006) no such lesion was
identified on the MR scan, but an area of increased radiotracer binding could be located in the clinically
relevant site. Two patients also demonstrated evidence [by location, admission computed tomography (CT)
appearance and diffusion-weighted imaging] of old ischaemic lesions (n = 4) acquired prior to the recent
clinical episode, probably asymptomatically. With regard to TSPO genotype, there were five HABs, three
MABs and two LABs in the sample, which was consistent with the reported distribution in the population
(Table 3).
Comparison of radiotracer uptake in ischaemic lesions
Across all lesions, the contrast between the lesion and the reference region was very similar, with
[11C]-(R)-PK11195 [TRR mean 1.20, standard deviation (SD) 0.28] and [18F]-GE180 without intravascular
activity correction (TRR mean 1.23, SD 0.36). With correction for [18F]-GE180 intravascular activity, the
visual image contrast and TRR increased (mean 1.46, SD 0.65). Example images are shown in Figure 1.
Our findings indicate the presence of microglial activation in most lesions 1–2 months after stroke, which
is in line with previous studies.6,8
As expected, recent infarcts showed higher ratios with both tracers than old infarcts. The mean TRRs of old
infarcts were 0.89 (SD 0.08) for [11C]-(R)-PK11195, 0.94 (SD 0.09) for [18F]-GE180 without correction for
intravascular activity and 0.89 (SD 0.06) with correction for intravascular activity (Figure 2).
TABLE 3 The characteristics and number of ischaemic lesions and genotype
Participant Recent infarct on MR
Contrast-enhancing infarct
on MR scan Old infarct on MR scan Genotype
P002 5 (unilateral) 4 0 HAB
P005 2 (unilateral) 0 0 HAB
P006 0a 0 0 HAB
P008 1 0 0 HAB
P009 1 0 0 LAB
P010 1 1 0 MAB
P011 1 n/a (not given for safety reason) 1 HAB
P012 1 1 0 MAB
P014 1 n/a (not given for safety reason) 3 (unilateral) MAB
P015 1 1 0 LAB
n/a, not applicable.
a One area of increased radiotracer binding located on the PET images in the clinically relevant site, at the correlation plots
included in the ‘recent, non-contrast-enhancing lesion’ group.
DOI: 10.3310/eme07010 EFFICACY AND MECHANISM EVALUATION 2020 VOL. 7 NO. 1
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Visi et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Across all lesions in HAB and MAB participants, the correlation coefficient between the tracers was 0.84
[95% confidence interval (CI) 0.60 to 0.94] without (Figure 3) and 0.80 (95% CI 0.52 to 0.92) with
correction for intravascular activity. The LAB participants (n = 2, P009 and P015) have been excluded from
these calculations because of negligible binding of [18F]-GE180, but are included in Figure 3 and marked by
green squares and blue triangles.
When restricting the analysis to recent lesions in HABs and MABs only, mean TRR was 1.29 (SD 0.26)
for [11C]-(R)-PK11195, 1.32 (SD 0.36) for [18F]-GE180 without correction for intravascular activity and 1.64
(SD 0.65) with correction for intravascular activity. Correlation coefficients were 0.80 (95% CI 0.45 to 0.94)
without and 0.79 (95% CI 0.42 to 0.93) with correction (Figure 4), which was similar to the results obtained
FIGURE 1 A contrast-enhancing recent ischaemic lesion (patient P012) can be identified onMRI scans in the left middle
cerebral artery territory (top left). The patchy low T2 signal within the infarct area on the FLAIR image (top right)
is consistent with haemorrhagic transformation, which had also been detected on the 24-hour post-thrombolysis
CT scan. The infarct area shows higher radiotracer uptake than the mirror region on both the [11C]-(R)-PK11195
(bottom left) and the [18F]-GE180 PET scan (bottom middle). Correction for intravascular activity on [18F]-GE180 PET










































FIGURE 2 [18F]-GE180 and [11C]-(R)-PK11195 uptake (TRR: mean and SD) in recent and old infarcts.
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FIGURE 3 Correlation of TRRs across all lesions (recent and chronic) between [11C]-(R)-PK11195 and [18F]-GE180











































FIGURE 4 Correlation of [11C]-(R)-PK11195 TRRs across recent lesions (HABs and MABs only) with (a) [18F]-GE180
TRRs without correction for intravascular activity and (b) with correction for intravascular activity. Correlation did
not depend on contrast enhancement on MRI (marked by different symbols).
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in all lesions. These figures also indicate that the correlation was similar for contrast-enhancing and
non-contrast-enhancing lesions while the former generally showed higher TRR values for both tracers.
The effect of genotype
Healthy tissue
As the genotype might affect radiotracer binding (LAB <MAB < HAB), we tested that hypothesis by rank-order
correlation. There was no significant association of binding [11C]-(R)-PK11195 in healthy contralateral tissue
with genotype (rho = –0.14, 95% CI –0.56 to 0.34) (Figure 5a) in our sample. In contrast, there was a
significant association of [18F]-GE180 tissue uptake (tissue activity concentration) with genotype (ρ = 0.64,
95% CI 0.11 to 0.89) (Figure 5b). Supressing the vascular contribution from the tissue activity, the difference
between LABs and MABs and HABs became more pronounced after correction of the tissue activity of
[18F]-GE180 for intravascular activity (Figure 5c), whereas the numerical correlation was somewhat less

























































































































FIGURE 5 Tissue activity by genotype in normal contralateral tissue. (a) [11C]-(R)-PK11195 binding potential;
(b) [18F]-GE180 tissue activity (kBq/ml) uncorrected; and (c) [18F]-GE180 tissue activity (kBq/ml) corrected for
intravascular activity.
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As shown in Table 4, tissue uptake of [18F]-GE180 with correction for intravascular activity in LABs was
approximately 25% of the uptake in MABs and HABs. Without correction, the [18F]-GE180 uptake values in
LABs were as high as 62–75% of the values in MABs and HABs. Normal tissue uptake of [18F]-GE180 with
correction in MABs and HABs was approximately 60% of the total signal without correction, indicating
that about 40% of the total signal came from intravascular activity.
Ischaemic lesions
A similar picture emerges in ischaemic lesions (Table 5): no correlation with genotype with [11C]-(R)-PK11195,
but a significant relation with [18F]-GE180 tissue activity concentration without correction for intravascular
activity (ρ = 0.50; p = 0.03) (Figure 6a) and with correction for intravascular activity (ρ = 0.53; p = 0.02
(Figure 6b).
Even in participants categorised as LAB, [18F]-GE180 uptake in lesions was considerably higher (corrected
activity values 0.570 and 0.303 kBq/ml) than in normal tissue (0.122 and 0.213 kBq/ml, respectively).
As shown in Table 6, tissue uptake of [18F]-GE180 with correction for intravascular activity in LABs was
approximately 50% of the uptake in MABs and HABs. Without correction, the [18F]-GE180 uptake values in
LABs were as high as 66–83% of the values in MABs and HABs. The tissue uptake of [18F]-GE180 with
correction in MABs and HABs was approximately 67% of the total uptake (without correction).
As indicated before, older infarcts showed less radiotracer uptake with both tracers than more recent infarcts.
Their distribution was not even between the three subgroups (0 out of 2 in the LABs, 3 out of 6 in the MABs,
1 out of 11 in the HABs). Thus, we also restricted the analysis to recent infarcts only (see Table 6), which did
not change the contrast between the groups with [18F]-GE180.
TABLE 4 [11C]-(R)-PK11195 binding potential and uptake of [18F]-GE180 in normal contralateral tissue
Genotype
[11C]-(R)-PK11195 BP [18F]-GE180 activity (kBq/ml)
[18F]-GE180 activity
(kBq/ml) – corrected
Mean SD Mean SD Mean SD
LAB 0.1000 0.2630 0.7615 0.1761 0.1675 0.0643
MAB 0.0025 0.1087 1.0362 0.0951 0.6377 0.0994
HAB 0.0045 0.1705 1.2291 0.2877 0.7195 0.2282
BP, binding potential.







Mean SD Mean SD Mean SD
LAB 0.3520 0.0085 0.9950 0.1782 0.4365 0.1888
MAB 0.0673 0.2230 1.1963 0.4335 0.8007 0.3426
HAB 0.2852 0.3766 1.5191 0.3533 1.0377 0.3110
BP, binding potential.
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Effect of blood–brain barrier disruption
Binding potentials measured with [11C]-(R)-PK11195 are higher in lesions with blood–brain barrier (BBB)
disruption, as demonstrated by gadolinium contrast enhancement, than in those without (p = 0.02, t-test)
(Figure 7).
Because of the strong effect of genotype on [18F]-GE180 binding, tissue activity concentration values cannot be
used without adjustment. This was done by using TRRs with lesion values divided by those in the corresponding
contralateral regions of interest. Lesions with BBB disruption also show increased uptake of [18F]-GE180 [t-test;
p = 0.004 (Figure 8a) without correction for intravascular activity and p = 0.003 (Figure 8b) with correction for
intravascular activity] in HAB and MAB patients. The single LAB patient with BBB disruption (P015) also showed
a very high lesion-to-reference ratio (1.76 without correction for intravascular activity, 4.67 with correction for
intravascular activity) contrary to expected negligible specific binding (see Figure 3). This suggests that BBB
damage is associated with significant non-specific radiotracer uptake that cannot be accounted for by
correction for intravascular activity.
Uptake values in non-enhancing lesions were very small and (in this pilot sample) not significantly different





















































































FIGURE 6 [18F]-GE180 tissue activity (kBq/ml) in ischaemic lesions by genotype. (a) Uncorrected for intravascular
activity; and (b) corrected for intravascular activity.







Mean SD Mean SD Mean SD
LAB 0.3520 0.0085 0.9950 0.1782 0.4365 0.1888
MAB 0.2127 0.1703 1.3583 0.2923 0.979 0.2687
HAB 0.3361 0.2347 1,5612 0.3324 1.0852 0.3094
BP, binding potential.
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FIGURE 7 Effect of BBB disruption on [11C]-(R)-PK11195 binding potential in ischaemic lesions. N, no; Y, yes.

































































FIGURE 8 The effect of BBB disruption on [18F]-GE180 uptake (TTR, relative to contralateral VOIs) in ischaemic
lesions, HAB and MAB patients only. (a) without correction for intravascular activity; and (b) with correction for
intravascular activity. N, no; Y, yes.
TABLE 7 [11C]-(R)-PK11195 and [18F]-GE180 uptake (ratios relative to contralateral VOIs) in recent lesions with and









Mean SD Mean SD Mean SD
No 0.0944 0.2899 1.1006 0.1748 1.2027 0.3096
Yes 0.5498 0.2391 1.6259 0.2743 2.2012 0.4934
BP, binding potential.
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Correlation between imaging and systemic inflammatory markers
Statistically significant correlation could be demonstrated between both plasma interleukin 6 and
high-sensitivity CRP levels and the lesion-to-reference ratios with [11C]-(R)-PK11195 and also marginally










































































FIGURE 10 Rank-order scatterplot of high-sensitivity CRP levels and TTRs.
TABLE 8 Rank correlation between inflammatory markers and lesion-to-reference ratios
Lesion-to-reference ratio
Interleukin 6 High-sensitivity CRP
ρ 95% CI ρ 95% CI
[11C]-(R)-PK11195 0.68 0.09 to 0.92 0.76 0.25 to 0.94
[18F]-GE180 TRR 0.63 0.001 to 0.90 0.63 0.001 to 0.90
[18F]-GE180 with correction for intravascular activity 0.57 –0.09 to 0.88 0.61 –0.03 to 0.90
RESULTS
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Three patients (i.e. P002, P006 and P015) had elevated interleukin 6 levels (7.7, 10.4 and 13.8 pg/ml) and
high-sensitivity CRP levels (8.17, 7.35, and 35 mg/l). The patients also showed higher lesion-to-reference
ratios with [11C]-(R)-PK11195 (TRR median 1.47, range 1.12–1.88) and [18F]-GE180 without intravascular
correction (TRR median 2.34, range 1.09–4.67) relative to the rest of the participants with normal inflammatory
marker levels [[11C]-(R)-PK11195, TRR median 1.02, range 0.86–1.35; and [18F]-GE180, TRR median 1.02, range
0.84–2.74]. As seen in Table 3, patients P002 and P015 also demonstrated the presence of obvious BBB
disruption (by having contrast-enhancing lesions), which also contributes to the higher radiotracer uptake.
Correlation with clinical outcome
The pilot phase of this study had not been powered to demonstrate associations with clinical outcome.
None of the imaging data or plasma markers showed an obvious association with clinical outcome.
Safety and tolerability
The mean score from the 10 participants’ tolerability questionnaire was 4.36 (range 4–5), which is well
above the threshold (neutral = 3) that we set to accept.
We did not observe any serious adverse events. Non-serious adverse events occurred, but had no obvious
links to the radiotracer.
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To our knowledge, this is the first study to analyse the properties of [
18F]-GE180 in patients with ischaemic
stroke and to compare it with [11C]-(R)-PK11195 in human participants. As to be expected with the
very small amounts of injected PET radiotracer, we did not observe any serious adverse events. Although
[18F]-GE180 provided very good contrast in ischaemic lesions with BBB damage, we also observed some
limitations that had not been seen in the generally favourable outcome of a previous stroke study in rats.19
Similar to previous studies of the kinetics of [18F]-GE180 in healthy human participants13,20 and in patients
with glioma21 and multiple sclerosis,22 but in contrast to rodent studies,19 we found that the uptake of
[18F]-GE180 in normal tissue across the intact BBB was very low.
Perfusion and blood volume in subacute ischaemic lesions can be highly variable, depending on the extent of
reperfusion.23 We therefore performed corrections for intravascular activity. We had opted for scanning times
not exceeding 30 minutes, as this length of time is typically required for clinically applicable procedures in
functionally impaired patients. The procedure was regarded as well tolerated as indicated by patient responses
in the questionnaire. However, because of the short data acquisition time, we could not perform standard
kinetic modelling and so estimated intravascular activity from data obtained during the first 5 minutes after
radiotracer injection. The correction improved signal-to-background contrast of [18F]-GE180, but did not
change the correlations between [18F]-GE180 and [11C]-(R)-PK11195 substantially.
As demonstrated in Figures 3 and 4, correlation was generally very good and lesion-to-background ratios
were comparable, suggesting that [18F]-GE180 could possibly be used instead of [11C]-(R)-PK11195 to assess
microglial activity in clinical stroke studies. We also found a correlation between systemic inflammation
markers and radiotracer uptake in lesions with both tracers, confirming observations previously seen in
normal participants with vascular risk factors.24 Neither systemic nor PET markers were related to clinical
outcome. However, the small sample in our pilot study had not been powered to address this question and
functional deficits had been mild already at study inclusion, leaving limited room for further improvement of
functional scores.
Recent infarcts showed higher radiotracer uptake with both tracers than old infarcts. In contrast with the recent
lesions, most of the old infarcts demonstrated less radiotracer uptake (i.e. TRR < 1) than the contralateral
reference region. In the absence of previous scans or obviously relevant clinical events, we could not
establish the exact age of the old infarcts. But some details in the clinical history (e.g. an episode of possibly
transitory ischaemic attack in the case of P011 and a few episodes of paroxysmal atrial fibrillation in the
case of P014) suggested that these might have been acquired many years before. A previous longitudinal
study9 demonstrated increased [11C]-(R)-PK11195 binding 150 days after the stroke onset. The lack of
inflammation in our case could perhaps be explained by the presence of an already established glial scar.
Substantial limitations for clinical use of [18F]-GE180 became obvious when analysing the effects of the
genetic polymorphism and BBB damage. We found a significant association of [18F]-GE180 tissue activity
concentration with genotype in both the healthy contralateral tissue and the ischaemic lesions, but not with
[11C]-(R)-PK11195. When applying correction for intravascular activity of [18F]-GE180, the difference between
MABs and HABs was no longer significant in healthy tissue. A similar effect was seen in other studies13,25 but
not in all studies20 conducted on healthy volunteers, perhaps because of the small magnitude of the signal
in a normal brain. The differences in binding of second-generation tracers across HAB/MAB/LAB classes vary
depending on ligand affinity.26 In vitro [18F]-GE180 demonstrates a binding affinity of 15 : 1 between HABs
and LABs, which suggests negligible specific binding in PET scans obtained in LABs.
Owing to the limited ability of [18F]-GE180 to cross the intact BBB and, therefore, the poor penetration of
the brain tissue, a significant amount of the signal in a brain region of interest is in fact from the vascular
activity. As the spatial resolution of human brain imaging is unable to resolve the vasculature, we sought
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to apply an approximate correction for the contribution of the vascular signal by subtracting an early
image. Our results suggest that a significant portion (up to 50%) of the signal seen in the infarcts in MAB
and HAB patients may be caused by spillover from the vasculature.
The comparison of lesions with and without contrast enhancement suggests that BBB disruption is playing a
major role in tissue uptake of [18F]-GE180 in ischaemic lesions. Although some proportion of increased uptake
will probably indicate increased binding to TSPO receptors, this was also observed in LABs, which suggested
that there is a large amount of non-specific uptake in ischaemic lesions with contrast enhancement. Thus,
clinical interpretation of findings would need to take into account the effects of the polymorphism and BBB
damage, which cannot be quantified accurately. Furthermore, assessment of BBB damage requires MR
scanning with gadolinium, which, for safety reasons, could not be applied in two of our patients.
Another challenge to the interpretation of clinical studies are recent in vitro findings27 suggesting that,
in contrast to findings in rodents, TSPO gene expression does not depend on microglia activation in
humans.
Given the significant impact of rs6971 genotype and BBB disruption on the signal, LABs and patients not
receiving contrast-enhanced MRI scans need to be excluded, which results in a substantial increase in the
size of the required sample. Furthermore, the statistical analysis would have taken the presence of contrast
enhancement into account as a major confounder. Considering these factors, the number of participants
planned for phase 2 (n = 40), which was aiming at correlation with clinical outcome, would not have
provided adequate power.
A limitation of the current study was the time window to assess TSPO binding with [18F]-GE180 (15–30 minutes
post injection). Most other studies report a time window of 60 to 90 minutes as the optimal interval. Kinetic
studies13,28 showed a relatively high contribution of intravascular blood activity to total observed activity, even
after 60 minutes. However, with late static scans, correction for intravascular activity is not possible and we
therefore chose scanning for 30 minutes immediately after injection. Analysis of kinetic data from multiple
studies (compiled in Sridharan29) showed relatively little change in lesion-to-background ratios after
15 minutes. In addition, the close correlation between [18F]-GE180 and [11C]-(R)-PK11195 that was observed
in our study supports the validity of using an early time window. Nevertheless, we cannot exclude that late
scanning could have provided increased lesion-to-background ratios.
DISCUSSION
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Chapter 6 Public and patient involvement
The study was discussed with a patient representative prior to finalising. This helped to confirm that thescanning protocol was practical and tolerable and that patient information sheets provided all of the
necessary information in an appropriate manner to ensure that proper informed consent of participants was
obtained. The interaction did not result in changes to the protocol. Owing to the very technical nature of
the results, publications will be primarily aimed at a specialist audience and we do not anticipate support by
public and patient involvement for dissemination of the results.
DOI: 10.3310/eme07010 EFFICACY AND MECHANISM EVALUATION 2020 VOL. 7 NO. 1
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Visi et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




This pilot study demonstrates that neuroinflammation in ischaemic stroke can be imaged by the TSPOPET radioligands [18F]-GE180 and [11C]-(R)-PK11195. Uptake in lesions, relative to contralateral tissue,
is similar and highly correlated with both radiotracers. As expected, [18F]-GE180 intravascular activity is
high during the entire scanning time, so correction for intravascular activity was necessary and could be
performed successfully. Genotype and BBB damage have significant effects on [18F]-GE180 uptake. High
uptake of [18F]-GE180 in lesions with BBB damage, even in LABs, suggests the presence of non-specific
binding, whereas uptake in normal brain tissue is very low. Further studies are warranted to fully
understand the influence of BBB damage on PET microglia imaging.
The very low uptake of [18F]-GE180 in normal brain tissue and the substantial confounding effect of BBB
damage had not been known when designing the present study. Thus, according to our own judgement
and the opinion of the Independent Data Monitoring Committee, phase 2 could not be conducted as
envisaged and the study has been closed after completion of phase 1.
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